The Maharashtra Food and Drug Administration seized gutkha worth over Rs 7 lakh from various parts of the state over the last two days in an effort to enforce the ban on gutkha sales.
The Maharashtra Food and Drug Administration has issued a show cause notice to a Pune-based diversified group for putting 'objectionable' label in its bottled mineral water and seized water bottles worth Rs 245,000 from Aurangabad.
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
The labs have been asked to submit their report within six weeks.
Dr Reddy's gets warning from US health regulator
Meticulous hand washing is your best bet to get rid of the grime that clings to the hand, that might harbour nasty pathogens, including the coronavirus.
'As a donor, you may think you are saving one life. But you touch the lives of the entire family and community associated with the person. And it only cost you a few hours of your life.'
The EUA allows for Remdesivir to be distributed in the US and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe condition.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
Speaking at the Conservative Political Action Committee in Orlando, Florida on Sunday, the 74-year-old leader, who left the White House on January 20, stopped short of announcing to run for the president in 2024, although he gave enough indications that he is moving in that direction.
The news comes as the United States approaches 300,000 deaths from COVID-19.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
DCGI, health ministry initiate dialogues with foreign regulators, try to understand global best practices
Last month, the US Food and Drugs Administration had placed Wockhardt's facilities in Waluj near Aurangabad on import alert, barring supply of various products from these facilities to the US.
Data also show that several other leading domestic pharma companies have recalled their products from the US
'We lost our place in being first in the epidemic, when it hit India so hard, but we were actually the epicentre of the epidemic from essentially April 2020, for almost an entire year. We had such high cases. We were the country that had the most mixed response.'
'The government had a vaccine from January.' 'The government should have given the vaccine to all population above the age of 45, right from the start.' 'Each state has its own problems, but as far as vaccine coverage in India is concerned, there have been mistakes.'
These vaccines have not yet been approved by the World Health Organization
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
the Maharashtra Food and Drug Administration on Saturday issued directives to various departments to cancel the licences of gutkha manufacturers, wholesalers and retailers in the state after finding magnesium carbonate in gutkha.
The US market for the drug is pegged at $1 billion. Cipla has been selling the product in the European market. It had won a similar case in the UK against GSK a couple of years ago.
Maggi noodles was recalled in June because some states had found presence of MSG and excessive lead content in the samples.
The move comes after a FDA notice to gutkha manufacturers to mention the contents of their product on the cover.
The move follows an FDA inspection of a Ranbaxy facility which identified significant violations of sound manufacturing practices.
This may include Rs 1,500 as a screening test for suspect cases and an additional Rs 3,000 for confirmation test, the guidelines said.
Sun Pharma's acquisition of Ranbaxy has once again revived evaluation of the troubled past of the latter, which had changed hands from the promoters merely five years ago.
Some US doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration.
With an increasing number of people from the Indian-American community playing a significant role in US elections, Congressman Raja Krishnamoorthi said there is a realisation among them that "if you don't have a seat at the table, you're on the menu -- that is why they are voting and running for office in large numbers".
These drugs will be entering in their global Phase -3 clinical trials early next year.
For Sun Pharma, it is an astute purchase that it hopes will not only boost its position in India but also globally.
The tests, according to the report, showed that Pepsi products from its plant in Khalapur in Raigad district contained 0.6 mg of lindane, which is above the permissible limits.
The Japanese company alleges the earlier Ranbaxy promoters withheld crucial information when they sold the company in 2008.
After recovering from issues such as defaults on foreign currency convertible bonds and piling debts, pharmaceutical major Wockhardt has been on the slow lane through the last six months, following warnings from global regulators such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency.
